Hydrogel could mean once-a-day breakthrough for cystic fibrosis treatment
A novel hydrogel technology that delivers drugs via the respiratory system has been developed by UK-based AGT Sciences. The company is aiming to use the technology for more efficient delivery of drugs used in the treatment of cystic fibrosis.
A novel hydrogel technology that delivers drugs via the respiratory system has been developed by UK-based AGT Sciences. The company is aiming to use the technology for more efficient delivery of drugs used in the treatment of cystic fibrosis.
AGT's hydrogel is made up almost entirely of water but can be used to encapsulate drugs in a nano-particulate form. Working with the Pharmaceutical Innovation CIC, AGT has recently demonstrated that this novel drug formulation can be delivered through commonly used nebulisers.
The next stage in the development of this technology is to move toward clinical trials. When inhaled by the patient, the nano-particles will penetrate deeper into the lungs and are less likely to be exhaled than conventional formulations.
'This is a key project for AGT Sciences that could not have progressed without the expertise and skills provided by the Pharmaceutical Innovation CIC,' said Gordon Feather, ceo of AGT Sciences.
Another benefit identified through the collaboration with the Pharmaceutical Innovation CIC was the potential to reduce the number of times cystic fibrosis patients will need to use a nebuliser. Trials using a laboratory lung model showed that the hydrogel allows a slow, linear release of drug over time. This could reduce the required frequency of drug administration from five times to a single daily dose.
AGT is working on a number of other healthcare applications of th technology in the areas of wound healing and cancer treatment.
